GLP-1 Receptor Agonists: Clinical Evidence and Patient Outcomes
GLP-1 receptor agonist patient outcomes reveal benefits beyond weight loss, including cardiovascular and metabolic improvements. Clinical evidence highlights both efficacy and potential adverse effects. Understanding these outcomes supports better…
Tirzepatide Cardiovascular Safety: Clinical Trial Evidence
Tirzepatide cardiovascular safety clinical trial evidence supports its use in managing cardiometabolic risks. Clinical trials show favorable cardiovascular outcomes with tirzepatide. This evidence aids clinicians in therapy selection for patients with…
Medical Cannabis Authorization Linked to Modestly Higher Heart Failure Risk in Large Ontario Study
This Ontario cohort study examines medical cannabis cardiovascular safety, finding a modestly higher heart failure risk among authorized patients. The hazard ratio was 1.15, indicating a 15% increased risk for heart failure-related events. These findings…
CBD Gummies and Heart Health: What the Evidence Really Shows for Everyday Use
CBD cardiovascular effects are a key concern for patients with heart conditions considering gummies. Current evidence shows mixed findings with limited long-term data on safety and drug interactions. Understanding these effects is essential for informed…
26-CCC-18139-ACC Arrhythmogenic Potential of Synthetic Cannabis – JACC
Synthetic cannabinoids arrhythmia presents significant cardiac risks distinct from natural cannabis. This study highlights the arrhythmogenic potential of synthetic cannabis compounds. Clinicians must recognize these risks for proper cardiac assessment…
Specific Forms of Substance Misuse Increase Stroke Risk – Psychiatry Advisor
Stroke risk assessment substance use is essential for identifying cerebrovascular dangers linked to different substances. Emerging evidence shows varying stroke risks depending on substance class and use patterns. Clinicians must incorporate…